Clin2
NCT06125041Likely a fitRecruiting

Adebelizumab with chemo and radiation for advanced lung cancer

Extensive Small Cell Lung Cancer

Part of Cancer, Lungs & breathing clinical trials.

This trial tests a new drug called Adebelizumab (an immunotherapy) combined with chemotherapy and radiation for people with extensive stage small cell lung cancer. The goal is to see if this combination helps shrink tumors and improves survival.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
51 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have extensive stage small cell lung cancer (cancer that has spread to a few other organs, but not more than 3 organs or 5 spots total).
  • You are in good physical shape (able to do daily activities without help).
  • You have not had chemotherapy or immunotherapy for this cancer before.
  • You can provide a tumor tissue sample (from a past biopsy or a new one).
  • Your blood tests show healthy levels of blood cells, liver, and kidney function.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06672133Not yet recruiting· Phase 3
Immunotherapy plus chemo and radiation for extensive-stage small cell lung cancer

This trial tests a combination of an immunotherapy drug (adebrelimab), chemotherapy, and radiation therapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if this combination helps people live longer and feel better.

NCT06236997Not yet recruiting· Phase 2
First-line treatment for extensive-stage small-cell lung cancer

This trial tests a new combination of immunotherapy (adebrelimab) with chemotherapy and radiation as the first treatment for extensive-stage small-cell lung cancer. It aims to see if this approach can help control the cancer better than standard treatments.

Zhengzhou, Henan
NCT06614621Not yet recruiting· Phase 2
Adebelimab plus chemotherapy for extensive-stage small cell lung cancer

This trial tests a new combination of an immunotherapy drug (adebelimab) with chemotherapy as a first treatment for extensive-stage small cell lung cancer. It aims to see if this combination can help control the cancer better than standard care.

NCT06768307Recruiting· Phase 2
Adebrelimab + Chemo with Radiation for Extensive-Stage SCLC

This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.

Beijing, Beijing Municipality
NCT06610734Recruiting· Phase 2
Combination treatment for extensive-stage small cell lung cancer

This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.

Sichuan
NCT07200154Not yet recruiting· Phase 2
Adebrelimab with chemoradiation for limited-stage small cell lung cancer

This trial tests a new drug (adebrelimab) combined with standard chemotherapy and radiation for limited-stage small cell lung cancer. After the initial treatment, the drug is continued to help keep the cancer from coming back.

Beijing, Beijing Municipality

Hear when a new Extensive Small Cell Lung Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.